The project aims at building an information network to provide comprehensive information on rare cancers to the community at large (oncologists, general practitioners, researchers, health authorities, patients). The final objectives are to improve the timeliness and accuracy of diagnosis, to facilitate the access to high quality treatment for patients with rare cancers, to identify centres of expertise for rare cancers in Europe and to standardize practices across Member States (MS).


HCV infects and affects a population in the EU who do not access care. The arrival of new curative HCV drugs are a great opportunity for those resourced to attend services and adhere to treatment, but this adherent population is the minority in the EU. If we aim to cure HCV in all risk groups we must take the treatment to the patient and vice-versa. The activities will support the development of national hepatitis strategies, screening and treatment guidelines, taking into account available treatment options. It will help to bridge primary, secondary care, and outreach in the community to facilitate access to and uptake of testing and treatment services particularly among key risk groups including drug users and homeless. It will also assess the potentially considerable economic impact of available treatment and testing strategies on health systems, which are under the responsibility of the EU Member States, with a view to inform decisions on balancing access to medicines with the financial sustainability of health systems. The HepCare project will contain six different components.HepCheck will aim at intensifying screening in the communityHepLink will link primary and secondary care HepEd will educate and up-skill healthcare professionals in the treatment of Hepatitis CHepFriend will provide a peer advocate support programme for patients to help treatment outcomesHepCost will assess the economic impact of the projectThe coordinator will have overall responsibility for disseminating the project impact and liaising with decision makers.The project will take place in 4 member states: Ireland, the UK, Spain and Romania.The HepCare Project will build on work undertaken by the European Commission, the European Centre for Disease Control and Prevention, and the European Monitoring Centre for Drugs and Drug Addiction with the aim of reducing morbidity and mortality related to hepatitis C and reducing the socioeconomic impact of hepatitis in the EU/EEA.


To establish a network of existing centres of expertise for dysmorphology in order to raise standards for diagnosis, management, and information exchange and dissemination, and to serve as a demonstration project for other EU networks of centres of expertise.


The objective of this project is to establish the European Haemophilia Network (EUHANET) to harmonise and improve the care received by European citizens with inherited bleeding disorders. The European Health Professionals and Patient Organisations will work together to enhance the quality of the delivered care. Criteria will be developed for the definition of levels of care provided by haemophilia centres and these will be applied to centres throughout Europe. A new public Haemophilia Central website will provide all the information relevant to patients with inherited bleeding disorders and their carers. EUHANET will also support collaboration between the expanded and developed pharmacovigilance system, the European Haemophilia Safety Surveillance System (EUHASS), and the new prospective Rare Bleeding Disorders Database (RBDD).


The general aim of this project is to build a network on autoinflammatory diseases in childhood. In particular the project would like to complete and integrate already existing initiatives in this field with the following actions:
- sensitize paediatricians and paediatric rheumatologists to the prompt recognition of these diseases,
- give a proper information among families affected by these conditions,
- increase the knowledge on the clinical presentation, response to treatment and complications of theses rare disorders.

